Does leaving residual fragments after percutaneous nephrolithotomy in patients with positive stone culture and/or renal pelvic urine culture increase the risk of infectious complications?


Journal

Urolithiasis
ISSN: 2194-7236
Titre abrégé: Urolithiasis
Pays: Germany
ID NLM: 101602699

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 26 03 2018
accepted: 01 06 2018
pubmed: 6 6 2018
medline: 24 12 2019
entrez: 6 6 2018
Statut: ppublish

Résumé

The residual fragments in patients with preoperative and intraoperative culture positivity may serve as an infection focus. The aim of this study was to assess the importance of residual fragments for developing SIRS in patients with stone culture and/or RPUC positivity. After obtaining institutional review board approval, a total of 729 patients who undergone PCNL for renal stones were included in this study. Residual fragments accepted to be positive if any fragment was detected irrespective of size. All patients were followed-up postoperatively for SIRS criteria. The patients were then followed-up for residual stone-related events and infectious complications. 94 of the 729 patients have developed SIRS postoperatively. SIRS positivity was more common among males and found to be associated with higher stone burden and presence of staghorn stone. Patients with residual fragments after PCNL also had higher rates of SIRS. In the subgroup analysis of 203 patients who had post-PCNL residual fragments, the peroperative stone and/or RPUC positivity was not found to be associated with the development of the SIRS. Although presence of residual fragments after PCNL is associated with SIRS development, stone culture and/or RPUC positivity has no additional risk for development of post-PCNL infectious complications in patients with residual fragments.

Identifiants

pubmed: 29869167
doi: 10.1007/s00240-018-1063-9
pii: 10.1007/s00240-018-1063-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

371-375

Références

Scand J Urol Nephrol. 1976;10(3):257-9
pubmed: 1006190
Crit Care Med. 2003 Apr;31(4):1250-6
pubmed: 12682500
J Urol. 2005 May;173(5):1610-4
pubmed: 15821509
Urology. 2006 Jan;67(1):26-9
pubmed: 16413326
J Med Assoc Thai. 2006 Jun;89(6):826-33
pubmed: 16850684
Eur Urol. 2007 Apr;51(4):899-906; discussion 906
pubmed: 17095141
J Endourol. 2006 Nov;20(11):870-4
pubmed: 17144853
Int Urol Nephrol. 2007;39(3):737-42
pubmed: 17294290
Int J Urol. 2008 Dec;15(12):1025-8
pubmed: 19120510
J Endourol. 2009 Jun;23(6):921-7
pubmed: 19473071
J Endourol. 2011 Jan;25(1):11-7
pubmed: 21247286
J Urol. 2011 Nov;186(5):1899-903
pubmed: 21944106
Eur Urol. 2012 Jun;61(6):1188-93
pubmed: 22244778
World J Urol. 2013 Oct;31(5):1135-40
pubmed: 22367718
Adv Urol. 2012;2012:813523
pubmed: 22829812
Urolithiasis. 2013 Oct;41(5):395-401
pubmed: 23712738
Nat Rev Urol. 2013 Oct;10(10):598-605
pubmed: 23999583
J Urol. 1986 Jan;135(1):15-7
pubmed: 3510316
Br J Urol. 1993 Sep;72(3):277-83
pubmed: 8220986

Auteurs

Tansu Degirmenci (T)

Department of Urology, HSU Izmir Bozyaka Training and Research Hospital, Saim Cikrikci Str. No: 59 Bozyaka, Izmir, Turkey.

Ibrahim Halil Bozkurt (IH)

Department of Urology, HSU Izmir Bozyaka Training and Research Hospital, Saim Cikrikci Str. No: 59 Bozyaka, Izmir, Turkey. ihalilbozkurt@yahoo.com.

Serdar Celik (S)

Department of Urology, HSU Izmir Bozyaka Training and Research Hospital, Saim Cikrikci Str. No: 59 Bozyaka, Izmir, Turkey.

Serkan Yarimoglu (S)

Department of Urology, HSU Izmir Bozyaka Training and Research Hospital, Saim Cikrikci Str. No: 59 Bozyaka, Izmir, Turkey.

Ismail Basmaci (I)

Department of Urology, HSU Izmir Bozyaka Training and Research Hospital, Saim Cikrikci Str. No: 59 Bozyaka, Izmir, Turkey.

Ertugrul Sefik (E)

Department of Urology, HSU Izmir Bozyaka Training and Research Hospital, Saim Cikrikci Str. No: 59 Bozyaka, Izmir, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH